Gilead Sciences, Inc. (TSX:GILD)
28.97
-0.15 (-0.52%)
Oct 6, 2026, 3:42 PM EST
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.80B USD in the quarter ending June 30, 2026, with 10.18% growth. This brings the company's revenue in the last twelve months to $30.46B, up 5.52% year-over-year. In the year 2025, Gilead Sciences had annual revenue of $29.44B with 2.40% growth.
Revenue (ttm)
$30.46B
Revenue Growth
+5.52%
P/S Ratio
5.88
Revenue / Employee
$1.79M
Employees
17,000
Market Cap
254.31B CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.44B | 689.00M | 2.40% |
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
| Dec 31, 2018 | 22.13B | -3.98B | -15.24% |
| Dec 31, 2017 | 26.11B | -4.28B | -14.09% |
| Dec 31, 2016 | 30.39B | -2.25B | -6.89% |
| Dec 31, 2015 | 32.64B | 7.75B | 31.13% |
| Dec 31, 2014 | 24.89B | 13.69B | 122.19% |
| Dec 31, 2013 | 11.20B | 1.50B | 15.46% |
| Dec 31, 2012 | 9.70B | 1.32B | 15.70% |
| Dec 31, 2011 | 8.39B | 435.97M | 5.48% |
| Dec 31, 2010 | 7.95B | 938.04M | 13.38% |
| Dec 31, 2009 | 7.01B | 1.68B | 31.40% |
| Dec 31, 2008 | 5.34B | 1.11B | 26.14% |
| Dec 31, 2007 | 4.23B | 1.20B | 39.78% |
| Dec 31, 2006 | 3.03B | 997.74M | 49.19% |
| Dec 31, 2005 | 2.03B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.20B |
| Extendicare | 1.98B |
| Curaleaf Holdings | 1.87B |
| Green Thumb Industries | 1.72B |
| WELL Health Technologies | 1.52B |
| Sienna Senior Living | 1.08B |
| Knight Therapeutics | 547.31M |
| DRI Healthcare Trust | 285.04M |
Gilead Sciences News
- 16 hours ago - Cognizant announces five-year extension of its work with Gilead Sciences - TheFly
- 1 day ago - Nurix Therapeutics announces second research term extension with Gilead - TheFly
- 5 days ago - More Upside Awaits for Gilead Sciences Stock. Stay Invested. - Barrons
- 6 days ago - Gilead put volume heavy and directionally bearish - TheFly
- 11 days ago - Genetic discovery yields clues toward reversal of Alzheimer's brain damage - Reuters
- 11 days ago - NTHM's Index Rebalance Puts Thematic Rotation to Work - ETF Trends
- 19 days ago - Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF - Business Wire
- 20 days ago - Gilead announces expanded scope of licensing agreements for lenacapavir - TheFly